Galectin Therapeutics Inc (GALT) — Who Owns This Stock? 13F Breakdown (Q2 2026)

GALT ranks #4531 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

103 institutions disclose a position in GALT, but none treat it as a major bet — even Great Point Partners LLC, its most concentrated holder, allocates just 0.7% of its own portfolio to it.

Ken Griffin has added to its GALT position for two straight quarters, increasing it by $2.4M to reach $2.5M today.

Susquehanna International Group, LLP has trimmed its GALT position for two straight quarters, cutting it by $2.1M while still holding $1.5M.

GALT is up 4% today, and institutions have been net buyers of $11.5M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

GALT reported a net loss of $30.8M in its latest fiscal year.

• Not yet profitable — net loss of $30.8M in the latest fiscal year
• Net income improved year over year, from -$47.0M to -$30.8M
• Operating cash flow was negative, using $23.9M in cash
• Current ratio of 2.42x — enough short-term assets to cover short-term liabilities